Organisation paid for research Program year 2025 Source: CMS Open Payments

Boston Clinicial Trials LLC

Neither a doctor nor a teaching hospital

Research payments

$1,907,471

77 payments

Through program year 2025, Boston Clinicial Trials LLC is reported as receiving $1,907,471 in research payments, across 77 payments.

By program year

6 rows
Year Kind Amount Payments
2025 Research $27,960 7
2024 Research $58,078 7
2023 Research $404,345 15
2022 Research $457,388 30
2021 Research $698,834 15
2020 Research $260,866 3

Breakdown

Who paid Research payments · program years 2020–2025
  1. Otsuka Pharmaceutical Development & Commercialization, Inc. $1,449,559 14 payments
  2. Biohaven Pharmaceutical Holding Company Ltd. $313,337 30 payments
  3. Pfizer Inc. $67,177 17 payments
  4. Biohaven Pharmaceuticals, Inc. $46,097 11 payments
  5. Sage Therapeutics, Inc. $31,301 5 payments
Studies the money was for Research payments · program years 2020–2025
  1. A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole As Adjunctive Therapy in the Maintenance Treatment of Adults With Major Depressive Disorder. $620,650 4 payments
  2. A Multi-Center, Randomized, Controlled Trial to Evaluate the Effectiveness of A Digital Therapeutic (CT-152) As Adjunctive Therapy in Adult Subjects Diagnosed With Major Depressive Disorder $334,339 3 payments
  3. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post-Traumatic Stress Disorder $241,449 3 payments
  4. Brexpiprazole as Combination Therapy With Sertraline in Treatment of Adults With PTSD $142,090 1 payment
  5. A Phase 4 Open-Label Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention $112,314 5 payments
  6. A Phase 4 Openlabel Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention $107,100 12 payments
  7. A Phase 2/3 Randomized Double-Blind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $85,340 9 payments
  8. An Open-Label, 52-Week, Multicenter Trial Evaluating the Long-Term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder $69,690 2 payments
  9. A Phase 23 Randomized Doubleblind Placebo Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention $43,256 8 payments
  10. A Phase 3, Multicenter, Randomized, Double-Blind Trial of Fixed-Dose Brexpiprazole As Combination Therapy With Sertraline in the Treatment of Adults With Post?Traumatic Stress Disorder $41,341 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record